Estimate of prevalent hyperuricemia by systemic inflammation response index: results from a rural Chinese population

References

• Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015 Sep;33(9):1729–41;discussion 1741.
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811–1821.
   PubMed Web of Science ®Google Scholar
• Johnson J, Bakris GL, Borghi C, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation. Am J Kidney Dis. 2018;71(6):851–865.
   PubMed Web of Science ®Google Scholar
• Lin W-Y, Liu C-S, Li T-C, et al. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (taichung community health Study). Ann Rheum Dis. 2008;67(3):432–433.
   PubMed Web of Science ®Google Scholar
• Stiburkova B, Pavelcova K, Pavlikova M, et al. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. Arthritis Res Ther. 2019 Mar 20;21(1):77.
   PubMedGoogle Scholar
• Nakayama A, Matsuo H, Nakaoka H, et al. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci Rep. 2014 Jun 9;4:5227.
   PubMed Web of Science ®Google Scholar
• Stiburkova B, Pavelcova K, Zavada J, et al. Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology (Oxford). 2017 Nov 1;56(11):1982–1992.
   PubMed Web of Science ®Google Scholar
• Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in mainland china from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011 Oct;63(10):3136–3141.
   PubMed Web of Science ®Google Scholar
• Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006 May;27(10):1174–1181.
   PubMed Web of Science ®Google Scholar
• Spiga R, Marini MA, Mancuso E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-kappaB signaling pathway in hepg2 cells. Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1241–1249.
   PubMed Web of Science ®Google Scholar
• Chen L, Lan Z. Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-kappaB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway. Food Funct. 2017 May 24;8(5):1785–1792.
   PubMed Web of Science ®Google Scholar
• Kaneko C, Ogura J, Sasaki S, et al. Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation. Biochim Biophys Acta Gen Subj. 2017 Mar;1861(3):559–566.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang N, et al. Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. Biomed Pharmacother. 2016 Oct;83:975–988.
   PubMed Web of Science ®Google Scholar
• Schorn C, Janko C, Munoz L, et al. Sodium and potassium urate crystals differ in their inflammatory potential. Autoimmunity. 2009 May;42(4):314–316.
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–96.
   PubMed Web of Science ®Google Scholar
• Maruhashi T, Hisatome I, Kihara Y, et al. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018 Nov;278:226–231.
   PubMed Web of Science ®Google Scholar
• El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. J Adv Res. 2017 Sep;8(5):487–493.
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016 Jul 15;122(14):2158–2167.
   PubMed Web of Science ®Google Scholar
• Xu L, Yu S, Zhuang L, et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget. 2017 May 23;8(21):34954–34960.
   PubMedGoogle Scholar
• Geng Y, Zhu D, Wu C, et al. A novel systemic inflammation response index (SIRI) for predicting postoperative survival of patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2018 Dec;65:503–510.
   PubMed Web of Science ®Google Scholar
• Chen M-Q, Shi W-R, Shi C-N, et al. Impact of monocyte to high-density lipoprotein ratio on prevalent hyperuricemia: findings from a rural Chinese population. Lipids Health Dis. 2020 Mar 16;19(1):48.
   PubMed Web of Science ®Google Scholar
• Wang HY, Shi WR, Yi X, et al. Value of reduced glomerular filtration rate assessment with cardiometabolic index: insights from a population-based Chinese cohort. BMC Nephrol. 2018 Oct 25;19(1):294.
   PubMedGoogle Scholar
• Shi WR, Wang HY, Chen S, et al. Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study. Lipids Health Dis. 2018 Oct 12;17(1):236.
   PubMedGoogle Scholar
• Gois PHF, Souza ERM. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2017 Apr;13(4):Cd008652.
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–1062.
   PubMed Web of Science ®Google Scholar
• Association. AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S13–s28.
   PubMedGoogle Scholar
• Alonso A, Sovell KA. Gout, hyperuricemia, and Parkinson’s disease: a protective effect? Curr Rheumatol Rep. 2010 Apr;12(2):149–155.
   PubMedGoogle Scholar
• Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008 Nov;26(11):2085–2092.
   PubMed Web of Science ®Google Scholar
• Chida R, Hisauchi I, Toyoda S, et al. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res. 2015 Nov;38(11):765–769.
   PubMed Web of Science ®Google Scholar
• Bagnati M, Perugini C, Cau C, et al. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J. 1999 May 15;340(Pt 1):143–152.
   PubMedGoogle Scholar
• Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005 May;67(5):1739–1742.
   PubMed Web of Science ®Google Scholar
• White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1044–1048.
   PubMed Web of Science ®Google Scholar
• Liang WY, Zhu XY, Zhang JW, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling. Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):187–194.
   PubMed Web of Science ®Google Scholar
• Cai W, Duan XM, Liu Y, et al. Uric acid induces endothelial dysfunction by activating the HMGB1/RAGE signaling pathway. Biomed Res Int. 2017;2017:4391920.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kwon M, Lee HY, et al. Higher pro-inflammatory dietary score is associated with higher hyperuricemia risk: results from the case-controlled Korean genome and epidemiology study_cardiovascular disease association study. Nutrients. 2019 Aug 5;11(8):1803.
   Web of Science ®Google Scholar
• Tan J, Wan L, Chen X, et al. Conjugated Linoleic acid ameliorates high fructose-induced hyperuricemia and renal inflammation in rats via NLRP3 inflammasome and TLR4 signaling pathway. Mol Nutr Food Res. 2019;63(12):e1801402.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li C, Duan S, et al. Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Biomed Pharmacothe. 2019;118:109195.
   PubMed Web of Science ®Google Scholar
• Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–935.
   PubMed Web of Science ®Google Scholar
• Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150(11):795–802.
   PubMed Web of Science ®Google Scholar
• Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–1384.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7(8):1355–1364.
   PubMed Web of Science ®Google Scholar
• Parikh CR, Thiessen-Philbrook H. Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease. J Am Soc Nephrol. 2014;25(8):1621–1629.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino  RB, D’Agostino  RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72; discussion 207–12.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011 Jan 15;30(1):11–21.
   PubMed Web of Science ®Google Scholar